-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Barclays PLC Increases Stake in 89bio, Inc. (NASDAQ:ETNB)
Barclays PLC Increases Stake in 89bio, Inc. (NASDAQ:ETNB)
Barclays PLC boosted its position in shares of 89bio, Inc. (NASDAQ:ETNB – Get Rating) by 1,490.0% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 388,982 shares of the company's stock after purchasing an additional 364,518 shares during the quarter. Barclays PLC owned about 1.91% of 89bio worth $2,252,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Acadian Asset Management LLC purchased a new stake in 89bio during the 1st quarter valued at about $34,000. Rhumbline Advisers purchased a new stake in 89bio during the 1st quarter valued at about $42,000. Mirabella Financial Services LLP purchased a new stake in 89bio during the 1st quarter valued at about $43,000. Virtu Financial LLC purchased a new stake in 89bio during the 2nd quarter valued at about $65,000. Finally, Cubist Systematic Strategies LLC grew its position in 89bio by 33.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,342 shares of the company's stock valued at $82,000 after purchasing an additional 6,410 shares during the last quarter. 87.78% of the stock is owned by hedge funds and other institutional investors.
Get 89bio alerts:Insider Transactions at 89bio
In other news, CFO Ryan Martins sold 5,947 shares of the stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $12.51, for a total value of $74,396.97. Following the transaction, the chief financial officer now owns 36,368 shares in the company, valued at approximately $454,963.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 11.80% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on ETNB shares. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $34.00 price target (up previously from $27.00) on shares of 89bio in a report on Monday, November 14th. Royal Bank of Canada dropped their price target on shares of 89bio from $35.00 to $29.00 and set an "outperform" rating on the stock in a report on Friday, November 11th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, 89bio has a consensus rating of "Buy" and a consensus target price of $25.25.89bio Price Performance
Shares of NASDAQ:ETNB opened at $12.70 on Friday. The firm's 50 day moving average price is $10.64 and its 200-day moving average price is $7.76. 89bio, Inc. has a twelve month low of $2.00 and a twelve month high of $12.95. The company has a quick ratio of 5.81, a current ratio of 5.81 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $591.06 million, a PE ratio of -2.91 and a beta of 0.80.
89bio (NASDAQ:ETNB – Get Rating) last issued its quarterly earnings data on Thursday, November 10th. The company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.32. Equities research analysts expect that 89bio, Inc. will post -2.65 EPS for the current year.
89bio Profile
(Get Rating)
89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis.
Further Reading
- Get a free copy of the StockNews.com research report on 89bio (ETNB)
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
- Mullen Automotive Stock Gains Momentum On Positive News
- Harley-Davidson Inc. Stock, Is It Time To Buy?
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air's Recent Earnings
Receive News & Ratings for 89bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 89bio and related companies with MarketBeat.com's FREE daily email newsletter.
据巴克莱最近提交给美国证券交易委员会的13F文件显示,今年第三季度,巴克莱将其在纳斯达克(Sequoia Capital:ETNB-GET Rating)的持股比例提高了1,490.0%。该基金在本季度额外购买了364,518股后,持有该公司388,982股股票。截至最近一次报告期末,巴克莱银行持有89Bio约1.91%的股份,价值2,252,000美元。
其他机构投资者最近也买卖了该公司的股票。Acadian Asset Management LLC在第一季度购买了89Bio的新股份,价值约3.4万美元。Rhumbline Advisers在第一季度购买了89Bio的新股份,价值约42,000美元。Mirabella Financial Services LLP在第一季度购买了89Bio的新股份,价值约43,000美元。Virtu Financial LLC在第二季度购买了89Bio的新股份,价值约6.5万美元。最后,立体主义系统战略有限责任公司在第二季度将其在89Bio的头寸增加了33.9%。Cubist Systems Strategy LLC在上个季度又购买了6410股,现在拥有25,342股该公司股票,价值82,000美元。87.78%的股票由对冲基金和其他机构投资者持有。
到达89Bio警报:89Bio的内幕交易
在其他消息方面,首席财务官瑞安·马丁斯在1月3日星期二的一笔交易中出售了5947股该公司股票。这些股票的平均价格为12.51美元,总价值为74,396.97美元。交易完成后,这位首席财务官现在拥有该公司36,368股股票,价值约454,963.68美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过美国证券交易委员会网站。公司内部人士持有该公司11.80%的股份。
分析师升级和下调评级
一些分析师最近发布了关于ETNB股票的报告。康托·菲茨杰拉德在11月14日周一的一份报告中重申了对89Bio的增持评级,并为89io的股价设定了34.00美元的目标价(之前为27.00美元)。在11月11日星期五的一份报告中,加拿大皇家银行将89Bio的目标价从35.00美元下调至29.00美元,并对该股设定了“跑赢大盘”的评级。七位股票研究分析师对该股的评级为买入,一位分析师对该公司股票的评级为买入。根据MarketBeat的数据,89Bio的共识评级为买入,共识目标价为25.25美元。89Bio性价比
纳斯达克:etnb上周五开盘报12.7美元。该公司的50日移动均线价格为10.64美元,200日移动均线价格为7.76美元。89Bio,Inc.的12个月低点为2.00美元,12个月高位为12.95美元。该公司的速动比率为5.81,流动比率为5.81,债务权益比为0.08。该股市值为5.9106亿美元,市盈率为-2.91,贝塔系数为0.80。
89Bio(纳斯达克代码:ETNB-GET Rating)最近一次发布季度收益数据是在11月10日星期四。该公司公布了本季度每股收益(0.57美元),比普遍预期的(0.89美元)高出0.32美元。股票研究分析师预计,89Bio,Inc.本年度每股收益将达到2.65美元。
89Bio简介
(获取评级)
89BioInc.是一家临床阶段的生物制药公司,专注于治疗肝脏和心脏代谢性疾病的疗法的开发和商业化。它的主要候选产品是pegozafermin,一种用于治疗非酒精性脂肪性肝炎的成纤维细胞生长因子21的糖基化类似物。
进一步阅读
- 免费获取股票新闻网站89Bio(ETNB)上的研究报告
- 凯西·伍兹的方舟创新ETF将在2023年反弹?
- 马伦汽车公司股票因利好消息而上涨
- 哈雷-戴维森公司的股票,是时候买入了吗?
- Meta平台的底部已经到了,波动性还没有结束
- 阿拉斯加航空公司近期收益分析
接受89Bio日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对89Bio和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧